➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Mallinckrodt
Colorcon
McKinsey
Baxter

Last Updated: August 3, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CIXUTUMUMAB

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for Cixutumumab

Trial ID Title Status Sponsor Phase Summary
NCT00186628 Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD Completed The Leukemia and Lymphoma Society Phase 2 To determine if Rituximab administered after allogeneic transplantation decreases the incidence of chronic GvHD
NCT00186628 Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD Completed Stanford University Phase 2 To determine if Rituximab administered after allogeneic transplantation decreases the incidence of chronic GvHD
NCT00520481 Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer Completed Eli Lilly and Company Phase 2 This single arm, multicenter, open-label, phase II study will enroll chemotherapy-naive patients with metastatic, histologically-confirmed adenocarcinoma of the prostate (stage M1 D2). Treatment will continue until there evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Non-surgically castrated patients must continue the use of LHRH agonists during protocol treatment.
NCT00617708 S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery Completed National Cancer Institute (NCI) Phase 1/Phase 2 This randomized phase I/II trial is studying the side effects and best dose of monoclonal antibody therapy when given together with gemcitabine hydrochloride and erlotinib hydrochloride and to see how well they work compared with giving gemcitabine hydrochloride and erlotinib hydrochloride alone as first-line therapy in treating patients with metastatic pancreatic cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving erlotinib hydrochloride and gemcitabine hydrochloride together with monoclonal antibody therapy may kill more tumor cells.
NCT00678769 Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer Completed National Cancer Institute (NCI) Phase 1 This phase I trial studies the side effects and best dose of cixutumumab and temsirolimus in treating patients with locally advanced or metastatic cancer. Monoclonal antibodies, such as cixutumumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab together with temsirolimus may kill more cancer cells.
NCT00683475 A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer Completed Eli Lilly and Company Phase 2 The purpose of this study is to determine whether IMC-A12 or IMC-1121B (ramucirumab) with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer (APIC).
NCT00684983 Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer Active, not recruiting Southwest Oncology Group Phase 2 This randomized phase II trial studies capecitabine and lapatinib ditosylate to see how well they work compared with capecitabine, lapatinib ditosylate, and cixutumumab in treating patients with previously treated human epidermal growth factor receptor 2 (HER2)-positive stage IIIB-IV breast cancer. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cixutumumab, can block the ability of tumor cells to grow and spread. It is not yet known whether capecitabine and lapatinib ditosylate are more effective when given with or without cixutumumab in treating breast cancer that has spread nearby or to other areas of the body.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Cixutumumab

Condition Name

Condition Name for
Intervention Trials
Stage IV Non-Small Cell Lung Cancer 3
Stage IV Adult Soft Tissue Sarcoma 3
Childhood Leiomyosarcoma 2
Stage III Adult Soft Tissue Sarcoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Carcinoma 9
Lung Neoplasms 8
Carcinoma, Non-Small-Cell Lung 7
Adenocarcinoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cixutumumab

Trials by Country

Trials by Country for
Location Trials
United States 403
Canada 15
Australia 3
New Zealand 1
Belgium 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
Illinois 20
California 20
New York 17
Michigan 17
Ohio 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cixutumumab

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 22
Phase 1/Phase 2 4
Phase 1 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 21
Active, not recruiting 8
Terminated 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cixutumumab

Sponsor Name

Sponsor Name for
Sponsor Trials
National Cancer Institute (NCI) 22
Eli Lilly and Company 7
ImClone LLC 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
NIH 22
Industry 12
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Express Scripts
Harvard Business School
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.